Union Health Minister Jagat Prakash Nadda formally released “Lung Cancer Treatment and Palliation: Evidence-Based Guidelines” on the eve of World Cancer Day, marking the first time India has developed a nationally contextualised, evidence-based framework dedicated to lung cancer. The document, developed by the Department of Health Research and the Directorate General of Health Services in collaboration with leading oncology experts and partner institutions, comprises 15 recommendations designed to standardise diagnosis, treatment and palliative care across both public and private healthcare facilities, from tertiary cancer centres to district hospitals.
For decades, oncologists across India have relied primarily on Western and European protocols not designed with the country’s infrastructure constraints, disease profile or resource diversity in mind. That dependence has resulted in significant variation in how lung cancer patients are managed depending on where they seek care. Releasing the guidelines, Nadda was direct about the shift India needed to make. India must not merely replicate international models, he said, but lead with indigenous, context-specific solutions suited to the country’s healthcare realities, disease burden and resource settings.
The guidelines have been made available on the DHR website, and a plain-language summary is being prepared to make the document accessible to patients, families and caregivers.
Dr Tirathram Kaushik, Senior Consultant in GI, HPB, Gynecological and Thoracic Oncology and Robotic Surgery at HCG Cancer Centre, described the release as a landmark. “Until the development of these guidelines, clinicians in India have often adopted Western or European approaches to the management of lung cancer that were not necessarily tailored for the Indian healthcare environment,” he said, adding that the framework now provides “a uniform approach for the diagnosis, treatment and palliation of lung cancer patients in both the public and private sector.”
Among the recommendations Dr Kaushik flagged as most consequential is the emphasis on early detection and screening for high-risk groups, particularly those exposed to tobacco, occupational hazards and environmental pollution. This marks a departure from a pattern in which diagnosis typically occurs only after symptoms appear, often at an advanced and less treatable stage. The guidelines also address treatment pathways across different stages of the disease, recommending the appropriate modality, whether surgery, chemotherapy, targeted therapy or radiotherapy, based on stage and available resources. Equally notable is the integration of palliative care from the point of diagnosis rather than reserving it for end-stage patients, with pain management, psychosocial support and rehabilitation built into the treatment plan from the outset.
The enthusiasm, Dr Kaushik noted, needs to be matched with an honest reckoning of what implementation will demand. Infrastructure gaps in rural and resource-limited settings, the absence of a national lung cancer screening programme, uneven workforce readiness and the lack of robust population-based cancer registries were all identified as barriers that could limit the guidelines’ reach without deliberate policy investment.
Dr Aravind Badiger, Technical Director at BDR Pharmaceuticals, pointed to the guidelines’ potential to reshape how multidisciplinary teams function in day-to-day practice. “The availability of a standardised framework will help multidisciplinary teams, including oncologists, surgeons, radiologists and palliative care experts, to agree on best practices that are evidence-based and context-relevant to the varied healthcare settings in India,” he said. The plain-language summary, he noted, would enable more meaningful counselling of patients and families on treatment options, expected outcomes and the role of palliative care.
Both experts stressed the need for structured follow-through from policymakers, professional bodies and hospitals if the guidelines are to move from paper to practice. Dr Badiger outlined a clear agenda: implementation frameworks at national, state and district levels; structured training programmes for oncologists, pulmonologists, radiologists and primary care physicians; inclusion of lung cancer screening in national non-communicable disease programmes; strengthened cancer registries to track real-world outcomes; and public awareness campaigns aimed particularly at non-smokers, given the rising incidence of lung cancer linked to air pollution and environmental risk factors.
Lung cancer remains one of the leading causes of cancer-related mortality in India, with late-stage diagnosis being a persistent and costly problem. The release of nationally contextualised guidelines is widely seen as a necessary foundation. But as clinicians note, the harder work lies in ensuring these recommendations reach the doctor at a district hospital with the same force they would a specialist at a premier cancer centre. That last mile will determine how much of this guideline’s promise actually reaches patients.
